BRISBANE, Calif., April 2, 2019 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company,
today announced it has signed an option agreement with Brammer Bio, a gene therapy contract development
and manufacturing organization, to secure access to large-scale AAV
manufacturing. Additionally, at Sangamo's new facilities in
Brisbane, California, construction
is underway of a Phase 1/2 cGMP manufacturing facility, which is
expected to be operational in 2020.
"Robust and nimble product development capabilities and access
to large-scale manufacturing capacity are strategically important
as we expand our plans to develop and commercialize AAV-based gene
therapy and genome editing candidates," said Andy Ramelmeier, Sangamo's Chief Manufacturing
and Quality Officer. "The facility we are building in Brisbane and our expanded access to
commercial-grade supply through Brammer
Bio will allow us to continue to meet our quality, cost and
timeline goals."
The agreement with Brammer Bio
provides Sangamo with access to dedicated AAV manufacturing
capacity up to 2000-L bioreactor scale capable of handling
large-scale, commercial -grade runs for products such as ST-920,
Sangamo's gene therapy product candidate for Fabry disease. The
agreement also allows Sangamo to leverage Brammer Bio's viral vector manufacturing
know-how in the new Sangamo facility in Brisbane in order to provide a seamless
transition from early development to late-stage clinical trials and
commercial-scale manufacturing.
"Brammer Bio and Sangamo have
worked together for more than a decade, and we are pleased to
continue to expand our strong relationship through this agreement,"
said Mark Bamforth, president and
CEO of Brammer Bio. "Once we close
the recently announced acquisition of Brammer Bio by Thermo Fisher Scientific, we will
be able to leverage their industry-leading scale and capabilities
in serving pharma and biotech customers and further support the
growth of gene therapy companies such as Sangamo."
About Brammer
Bio
Brammer Bio
provides clinical and commercial supply of vectors for in
vivo gene therapy and ex vivo gene-modified cell
therapy, along with process and analytical development, and
regulatory support, enabling large pharma and biotech clients to
accelerate the delivery of novel medicines to improve patients'
health. Brammer is Helping to Cure®. Brammer is
owned by Ampersand Capital Partners, the only institutional
investor in the company, and its founders.
About Sangamo Therapeutics
Sangamo
Therapeutics, Inc. is focused on translating ground-breaking
science into genomic medicines with the potential to transform
patients' lives using gene therapy, ex vivo
gene-edited cell therapy, in vivo
genome editing, and gene regulation. For more
information about Sangamo, visit www.sangamo.com.
Forward-Looking Statements
This press release contains forward-looking statements based
on Sangamo's current expectations. These forward-looking statements
include, without limitation, statements related to the anticipated
benefits to Sangamo of its option agreement with
Brammer Bio, including anticipated
access to large-scale AAV manufacturing, the anticipated
operational status of Sangamo's planned manufacturing facility and
the timing thereof, Sangamo's expectation that its planned
manufacturing facility and access to commercial-grade supply
through Brammer Bio will allow
Sangamo to continue to meet its quality, cost and timeline
goals, statements related to Sangamo's potential growth, and
other statements that are not historical fact. Actual results may
differ materially from these forward-looking statements due to a
number of factors, including risks and uncertainties relating to
the complex and difficult nature of manufacturing biological
components; the ability for Sangamo to successfully collaborate
with Brammer Bio; Sangamo's
dependence on Brammer Bio for
manufacturing support; potential delays in or the inability to
complete the build out of Sangamo's planned manufacturing facility;
Sangamo's lack of experience as a company in manufacturing biologic
products which inexperience could result in adverse regulatory
actions or otherwise undermine its ability to utilize its planned
manufacturing facility for its own manufacturing needs; whether
clinical studies conducted by Sangamo will validate the safety and
efficacy of its product candidates; and Sangamo's ability to
develop commercially viable products. For a more detailed
discussion of these and other risks, please see Sangamo's SEC
filings, including the risk factors described in its Annual Report
on Form 10-K for the year ended December 31,
2018. Sangamo Therapeutics, Inc. assumes no obligation to
update the forward-looking information contained in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sangamo-announces-agreement-securing-access-to-large-scale-commercial-grade-manufacturing-capacity-at-brammer-bio-300822612.html
SOURCE Sangamo Therapeutics, Inc.